Week of August 13, 2012: Bristol-Myers Squibb Completes Acquisition of Amylin; Quintiles Acquires Expression Analysis; and More
Bristol-Myers Squibb Completes Acquisition of Amylin; Quintiles Acquires Expression Analysis; and More.
Bristol-Myers Squibb (BMS) has successfully completed its tender offer of Amylin Pharmaceuticals through its wholly owned subsidiary, B&R Acquisition Company, for all outstanding shares of common stock of Amylin at a purchase price of approximately $31 per share. Read More
Pfizer and AstraZeneca have entered into an agreement for the OTC rights for Nexium (esomeprazole magnesium), for treating gastroesophageal reflux disease. Under the agreement, Pfizer will acquire the exclusive global rights to market Nexium for the approved OTC indications in the US, Europe, and the rest of the world. Under the agreement, Pfizer will make an upfront payment of $250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone and royalty payments based on product launches and sales. Read More
The CRO Quintiles has acquired Expression Analysis, a provider of genomics testing and analysis to biopharmaceutical, academic, government, and nonprofit clients. Read More
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
